# AimRJU

#### **Novel Biologic RNA Therapeutics**

Aiming Yu, Founder & President yu@aimrna.com; 916-412-9045

#### **Growing Market Opportunity**



- RNA based therapy is a validated approach with the approval of eight drugs by the FDA
- Four ASO drugs and two siRNA drugs approved by the FDA in recent years
- Eight RNA based COVID-19 vaccines in pre-clinical or phase 1 trials



# AimRNA's Differentiated Solution & Benefits of Bioengineered RNAs

# Aim

- Novel technology & streamlined platform to produce a wide variety of biologic RNA molecules including ncRNA, miRNAs, siRNAs, aptamers, ASOs, sRNAs, etc.
  - Larger yield / scale tens milligrams of pure RNAs from 1 L of fermentation
  - Cost effective
- Biologic RNAs are more effective than synthetic counterparts
  - Folded & tolerated within living cells
  - Higher activity than synthetic counterparts
  - "Prodrug" strategy
- Enables in-house development of biologic RNA therapeutics to combat various diseases including lethal cancers

#### **Benefits of Bioengineered RNAs**



#### **Biological RNAs** (made in LIVING cells)

- Large scale (mg RNA/L culture)
- No/minimal natural modifications
- Variable lengths (e.g., 20-300 nt)
- Folded in living cells
- Tolerated by cells; safety needs more extensive studies
   More affordable with greatly reduced cost of goods


#### Synthetic RNAs

(by chemical synthesis)

- Large scale (automated)
- Extensive chemical modifications
- □ Variable with desired short length (e.g., <60 nt)
- Under chemical environment; proper folding?
- □ Size, sequence and modifications affect safety
- Less affordable; expensive with increased size)

#### AIMRNA34 Reduces Tumor Burden in Lung Cancer Mouse Models

AimRN




Ho et al., JPET, 365:494 (2018)

Wang et al., JPET, 354:131 (2015)

AimRNA, Inc.


#### AIMRNA34 Improves Overall Survival of Tumor Bearing Mice



Jian et al. Oncotarget (2017)

#### **AIMRNA7** for the treatment of HCC

## AimRN



AimRNA, Inc.

Jilek et al., MTNA (2019)

7

#### Team

## Aim



#### Aiming Yu, Ph.D. – Founder & President

20+ years of experience in drug development, DM/PK/PD, miRNA research, and cancer therapy.



Neelu Batra, Ph.D. – Scientist 5+ years in cancer therapy and RNA bioengineering technology.



Meijuan Tu, Ph.D. – Scientist 9+ years experience in pharmaceutical sciences and 4+ years in RNA based cancer therapy.



Primo N. Lara, M.D. – Advisor Physician Scientist – 25+ years of experience in clinical practice and research on new therapies.



Kit S. Lam, M.D., Ph.D. – Advisor Physician Scientist – 38+ years of experience in anti-cancer drug development, drug delivery, imaging, etc.

#### **IP & Regulatory Strategy**




Intellectual Property	Regulatory
<ul> <li>Strong IP protection for RNA production platform technology and BERA drug candidates</li> </ul>	Production at the GMP facility at UC Davis
<ul> <li>Exclusive right to license patent from UC Davis</li> </ul>	<ul> <li>Gathering GLP pharm/tox data ahead of pre-IND meeting with FDA</li> </ul>

#### Raising \$500,000 to fund IND-enabling studies

### **AimRNA's Emerging Pipeline**





# AimRJU

- Novel RNA bioengineering platform technology
- One-of-a-kind biological RNA molecules
- Lead candidates for cancer therapy

Aiming Yu, Founder & President yu@aimrna.com; 916-412-9045